Interleukin-36 in Infectious and Inflammatory Skin Diseases
暂无分享,去创建一个
[1] J. Seneschal,et al. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. , 2019, JCI insight.
[2] M. Herbst-Kralovetz,et al. IL‐36&ggr; induces a transient HSV‐2 resistant environment that protects against genital disease and pathogenesis , 2018, Cytokine.
[3] T. Bieber,et al. Candida induces the expression of IL‐36γ in human keratinocytes: implications for a pathogen‐driven exacerbation of psoriasis? , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] E. Eisenmesser,et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment , 2018, Cell Death & Disease.
[5] S. Gaffen,et al. IL-36 and IL-1/IL-17 Drive Immunity to Oral Candidiasis via Parallel Mechanisms , 2018, The Journal of Immunology.
[6] S. Akira,et al. Regnase-1, an Immunomodulator, Limits the IL-36/IL-36R Autostimulatory Loop in Keratinocytes to Suppress Skin Inflammation. , 2018, The Journal of investigative dermatology.
[7] Seamus J. Martin,et al. Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases , 2018, Cell Death & Disease.
[8] L. Tsoi,et al. RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature , 2018, Front. Immunol..
[9] L. Qing,et al. Elevated production of IL-36α in chronic hepatitis B virus-infected patients correlates with viral load. , 2017, Microbial pathogenesis.
[10] B. Lüscher,et al. The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function , 2017, Scientific Reports.
[11] G. Núñez,et al. Staphylococcus aureus Virulent PSMα Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-Dependent Skin Inflammation. , 2017, Cell host & microbe.
[12] R. Geha,et al. Staphylococcus aureus Epicutaneous Exposure Drives Skin Inflammation via IL-36-Mediated T Cell Responses. , 2017, Cell host & microbe.
[13] T. Tsai,et al. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness , 2017, Therapeutic advances in musculoskeletal disease.
[14] F. Ciccarelli,et al. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target , 2017, Science Translational Medicine.
[15] Hongzhong Jin,et al. IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis , 2017, International journal of medical sciences.
[16] L. Jensen. Interleukin-36 cytokines may overcome microbial immune evasion strategies that inhibit interleukin-1 family signaling , 2017, Science Signaling.
[17] D. Mennerich,et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies , 2017, mAbs.
[18] S. Uppalapati,et al. Interleukin-36β provides protection against HSV-1 infection, but does not modulate initiation of adaptive immune responses , 2017, Scientific Reports.
[19] M. Ghannoum,et al. The Mycobiome: Impact on Health and Disease States , 2017, Microbiology spectrum.
[20] Seamus J. Martin,et al. Neutrophil extracellular traps can serve as platforms for processing and activation of IL‐1 family cytokines , 2017, The FEBS journal.
[21] R. Pawliczak,et al. Correlation between IL36α and IL17 and Activity of the Disease in Selected Autoimmune Blistering Diseases , 2017, Mediators of inflammation.
[22] T. Denning,et al. IL-36γ signaling controls the induced regulatory T cell – TH9 cell balance via NFκB activation and STAT transcription factors , 2017, Mucosal Immunology.
[23] A. Giatromanolaki,et al. Successful response in a case of severe pustular psoriasis after interleukin‐1β inhibition , 2017, The British journal of dermatology.
[24] Yibing Yin,et al. Interleukin 36&agr; Attenuates Sepsis by Enhancing Antibacterial Functions of Macrophages , 2016, The Journal of infectious diseases.
[25] D. Jarrossay,et al. Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. , 2016, Cytokine.
[26] T. Standiford,et al. IL‐36γ is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components , 2016, Journal of leukocyte biology.
[27] M. Herbst-Kralovetz,et al. IL-36γ Augments Host Defense and Immune Responses in Human Female Reproductive Tract Epithelial Cells , 2016, Front. Microbiol..
[28] A. Alase,et al. Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist , 2016, Scientific Reports.
[29] Seamus J. Martin,et al. Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines. , 2016, Cell reports.
[30] O. Inatomi,et al. Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.
[31] S. Melgar,et al. IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation , 2016, Mucosal Immunology.
[32] T. Denning,et al. Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage , 2016, The Journal of Immunology.
[33] B. Le Goff,et al. Distinct expression of interleukin (IL)‐36α, β and γ, their antagonist IL‐36Ra and IL‐38 in psoriasis, rheumatoid arthritis and Crohn's disease , 2015, Clinical and experimental immunology.
[34] P. Saas,et al. Faculty Opinions recommendation of Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage. , 2015 .
[35] C. Gabay,et al. The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases. , 2015, Cytokine.
[36] D. Hashimoto,et al. Synergistic Proinflammatory Responses by IL-17A and Toll-Like Receptor 3 in Human Airway Epithelial Cells , 2015, PloS one.
[37] D. Mennerich,et al. Signal Transduction and Intracellular Trafficking by the Interleukin 36 Receptor* , 2015, The Journal of Biological Chemistry.
[38] S. Thomsen,et al. Off‐label use of TNF‐alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients , 2015, Dermatologic therapy.
[39] Mayte Suárez-Fariñas,et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. , 2015, The Journal of allergy and clinical immunology.
[40] Michael Hölzel,et al. IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. , 2015, The Journal of investigative dermatology.
[41] P. Barrow,et al. IL-36α induces maturation of Th1-inducing human MDDC and synergises with IFN-γ to induce high surface expression of CD14 and CD11c. , 2015, Human immunology.
[42] H. Mühl,et al. Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury , 2015, Scientific Reports.
[43] T. Torres,et al. Nail psoriasis as a predictor of the development of psoriatic arthritis. , 2015, Actas dermo-sifiliograficas.
[44] S. Jennings,et al. Animal models of herpes simplex virus immunity and pathogenesis , 2014, Journal of NeuroVirology.
[45] Z. Hajheydari,et al. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis , 2014, International journal of dermatology.
[46] Fabian J Theis,et al. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema , 2014, Science Translational Medicine.
[47] A. Smahi,et al. Is it relevant to use an interleukin‐1‐inhibiting strategy for the treatment of patients with deficiency of interleukin‐36 receptor antagonist? , 2014, The British journal of dermatology.
[48] M. Schön,et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations , 2014, The British journal of dermatology.
[49] J. Gudjonsson,et al. IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin , 2013, The Journal of Immunology.
[50] D. Boraschi,et al. The interleukin-1 receptor family. , 2013, Seminars in immunology.
[51] M. Gresnigt,et al. Biology of IL-36 cytokines and their role in disease. , 2013, Seminars in immunology.
[52] N. Balato,et al. The balance between pro‐ and anti‐inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL‐1 family members , 2013, Experimental dermatology.
[53] Rui-Xing Yin,et al. Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies. , 2013, International journal of cardiology.
[54] A. Smahi,et al. First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With Anakinra , 2013, Pediatrics.
[55] A. Armstrong,et al. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. , 2013, Journal of the American Academy of Dermatology.
[56] L. Joosten,et al. The IL‐36 receptor pathway regulates Aspergillus fumigatus‐induced Th1 and Th17 responses , 2013, European journal of immunology.
[57] H. Nakai,et al. Mutation Analysis of the IL36RN Gene in 14 Japanese Patients with Generalized Pustular Psoriasis , 2013, Human mutation.
[58] A. Derer,et al. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium , 2012, Annals of the rheumatic diseases.
[59] S. Werner,et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. , 2012, The Journal of clinical investigation.
[60] F. Sallusto,et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. , 2012, Blood.
[61] H. Mühl,et al. IL-36γ/IL-1F9, an Innate T-bet Target in Myeloid Cells* , 2012, The Journal of Biological Chemistry.
[62] F. Niyonsaba,et al. Interleukin-36 cytokines enhance the production of host defense peptides psoriasin and LL-37 by human keratinocytes through activation of MAPKs and NF-κB. , 2012, Journal of dermatological science.
[63] B. Medoff,et al. IL-36α Exerts Pro-Inflammatory Effects in the Lungs of Mice , 2012, PloS one.
[64] J. Sims,et al. IL-36 in psoriasis. , 2012, Current opinion in pharmacology.
[65] K. Horiuchi,et al. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand–dependent terminal keratinocyte differentiation , 2012, The Journal of experimental medicine.
[66] Li-Hua Lian,et al. The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36γ. , 2012, The Journal of investigative dermatology.
[67] Julia Oh,et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis , 2012, Genome research.
[68] H. Orzechowski,et al. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[69] P. Barrow,et al. Expression of IL‐1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL‐1F8 and IL‐1F9 , 2012, European journal of immunology.
[70] L. Joosten,et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist , 2012, Proceedings of the National Academy of Sciences.
[71] Yijun Carrier,et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. , 2011, The Journal of investigative dermatology.
[72] H. Dinh,et al. IL-36R ligands are potent regulators of dendritic and T cells. , 2011, Blood.
[73] C. Gabel,et al. Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) Activity , 2011, The Journal of Biological Chemistry.
[74] M. Simpson,et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. , 2011, American journal of human genetics.
[75] A. Smahi,et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.
[76] P. Avila,et al. Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. , 2011, American journal of respiratory cell and molecular biology.
[77] James T. Elder,et al. IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression , 2011, The Journal of Immunology.
[78] L. Joosten,et al. IL-1 family nomenclature , 2010, Nature Immunology.
[79] A. Smahi,et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. , 2010, Annals of internal medicine.
[80] Anna-Katharina Müller,et al. Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis , 2010, The Journal of cell biology.
[81] C. Gabel,et al. Externalization of the Leaderless Cytokine IL-1F6 Occurs in Response to Lipopolysaccharide/ATP Activation of Transduced Bone Marrow Macrophages , 2009, The Journal of Immunology.
[82] J. J. Taylor,et al. Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide , 2009, Clinical and experimental immunology.
[83] A. Rademaker,et al. Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity , 2009, Pediatrics.
[84] M. Lynch,et al. IL‐1F5 mediates anti‐inflammatory activity in the brain through induction of IL‐4 following interaction with SIGIRR/TIR8 , 2008, Journal of neurochemistry.
[85] H. Dinh,et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation , 2007, The Journal of experimental medicine.
[86] Roberta B Carey,et al. Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.
[87] J. Segre,et al. Epidermal barrier formation and recovery in skin disorders. , 2006, The Journal of clinical investigation.
[88] Ryan M. O’Connell,et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. , 2006, Immunity.
[89] K. Rabe,et al. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. , 2005, Physiological genomics.
[90] A. Bowcock,et al. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.
[91] J. Sims,et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-κB and MAPKs* , 2004, Journal of Biological Chemistry.
[92] N. Rothwell,et al. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells , 2003, Journal of Neuroimmunology.
[93] J. E. Ford,et al. A new nomenclature for IL-1-family genes. , 2001, Trends in immunology.
[94] J. Sims,et al. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. , 2001, Trends in immunology.
[95] R. Kastelein,et al. Two Novel IL-1 Family Members, IL-1δ and IL-1ε, Function as an Antagonist and Agonist of NF-κB Activation Through the Orphan IL-1 Receptor-Related Protein 21 , 2001, The Journal of Immunology.
[96] E. Christophers. Psoriasis − epidemiology and clinical spectrum , 2001, Clinical and experimental dermatology.
[97] I. Berdicevsky,et al. Incidence of Candida in psoriasis – a study on the fungal flora of psoriatic patients , 2001, Mycoses.
[98] J. E. Ford,et al. Organization of the human interleukin-1 receptor antagonist gene IL1HY1 , 2000, Immunogenetics.
[99] M. Doyle,et al. Identification and Initial Characterization of Four Novel Members of the Interleukin-1 Family* , 2000, The Journal of Biological Chemistry.
[100] Dirk E. Smith,et al. Four New Members Expand the Interleukin-1 Superfamily* , 2000, The Journal of Biological Chemistry.
[101] J. E. Ford,et al. IL1HY1: A novel interleukin-1 receptor antagonist gene. , 1999, Biochemical and biophysical research communications.
[102] F. Lowy. Staphylococcus aureus infections. , 2009, The New England journal of medicine.
[103] D. Greaves,et al. The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci. , 1998, Genomics.